Biopharmaceutical Contract Manufacturing: New Report Documents Industry Growth
Summary
Some of the large pharmaceutical companies are making strategic shifts away from full integration, moving toward more outsourcing to avoid capital expenditures, to gain access to expertise and capacity, and to shorten the time to market. "Outsourcing is attractive because it provides the flexibility needed whether a product fails in clinical trials or proves to be a tremendous success," explains Sandra Fox, president of HighTech Business Decisions. "This attractiveness, combined with suppliers expanding capacity and expertise and the increasing number of biopharmaceuticals entering the pipeline indicate the industry is in for a substantial growth cycle. SmithKline Beecham Biopharmaceuticals has entered the market by offering contract manufacturing services focusing on mammalian cell culture. The new 500-page report includes an analysis of the rapidly evolving biopharmaceutical contract manufacturing market, summaries of interviews conducted by Ph.D. level analysts with 45 pharmaceutical and biotechnology manufacturing directors worldwide, and profiles of 66 supplier companies.